glp 1 drugs how they work glucagon-like peptide receptor agonists How GLP-1 Medications Actually Work

J Thermoplast Compos Mater

Both oxidative damage to cells and reduced antioxidant capacity contribute to this disease

View Study Ricard-Blum S

Purohit TJ, Hanning SM, Wu Z (2018) Advances in rectal drug delivery systems

Although Sorafenib is a kinase inhibitor with multiple targets including RTKs and RAF, its treatment did not affect the total tyrosyl phosphorylation and ERK phosphorylation in TamR cells (Figure S5), indicating that inhibition of TamR ER+ breast cancer cell growth by Sorafenib under the concentration used is not through inhibition of RTKs and RAF

While the mechanism is still unclear, it could implicate Ras/Raf-1 which change the MOR, a GPCR, into a receptor tyrosine kinase like-complex (Zhang et al., 2013)